Stockholm, Sweden, June 27, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that professor Lars Lannfelt resumes his employment in the company as of September 1, 2018. Professor Lannfelt is one of the two founders, member of the Board, the largest owner and has today a consultancy role in the company. In the future he will work full-time as scientific expert with new discovery opportunities and continue to be the company’s contact person in the strategically important collaborations with research groups at the universities.
Associate Professor Pär Gellerfors founded BioArctic in 2003 together with professor Lannfelt and is the second largest owner, member of the Board and has during his employment mainly worked with business strategies. Gellerfors will leave his employment in the company as of September 1, 2018 and remains as member of the Board.
“I’m very pleased that professor Lannfelt has chosen to resume his employment in BioArctic. His recognized vast scientific expertise in neurodegenerative diseases and discoveries in Alzheimer’s disease will continue to benefit BioArctic,” says Gunilla Osswald, CEO of BioArctic. ”I would also like to thank Pär Gellerfors for his outstanding engagement in developing BioArctic to the company it is today and look forward to continued good collaboration with him on the Board level.”
For more information, please contact
Gunilla Osswald, PhD, CEO
Telephone: + 46 8 695 69 30
Christina Astrén, IR and Communications Director
Telephone: + 46 70 835 43 36
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact persons above, on June 27, 2018, at 07.00 am CET.
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.
BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (Nasdaq Stockholm: BIOA B). www.bioarctic.com